Should i exchange pfizer shares for zoetis

Building on a year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. It has more than 9, employees worldwide and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries.

Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in countries. For more information on the company, visit www. Words such as anticipate, expect, project, intend, plan, believe, and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements.

These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to differ materially from those expressed in, or underlying, those forward-looking statements is detailed in the filings of Pfizer and Zoetis with the SEC, such as annual and quarterly reports and the registration statement, the prospectus part thereof and related exchange offer documents.

Pfizer and Zoetis disclaim any obligation to update and revise statements contained in these materials based on new information or otherwise. Zoetis has filed a registration statement on Form S-4 File No. The Prospectus, which is included in the registration statement, contains important information about Pfizer, Zoetis, the exchange offer and related matters. Pfizer has delivered the Prospectus to its shareholders. Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Investing Best Accounts. Stock Market Basics. Stock Market. Industries to Invest In. Getting Started. Planning for Retirement. Retired: What Now? Personal Finance. Credit Cards. About Us. Who Is the Motley Fool? Fool Podcasts. Pfizer retained an 80 percent stake in Zoetis after the IPO and now plans to unwind that, starting with this offer.

The move comes as Pfizer continues to unload its non-pharmaceuticals businesses to focus on its core prescription drugs business, which has far higher profit margins. The premium is meant to encourage Pfizer shareholders to acquire Zoetis shares. Pfizer owns ,, shares of Zoetis Class B common stock that it will convert to Class A shares for the exchange. Pfizer shareholders must request at least